I think the key will be the duration of the response. From my understanding, everyone pooh-poohed chemogenex's auroa inhibitor because the duration of response is very short. 534 should work like gleevec in T315I if it lives up to its expectation. We will see this data in ASH.
Dr. Bio, Chemgenex omecataxine is not a very good drug and I believe it's questionable whether it will be approved in CML. This compound is a gimmick. Any chemo will do the same thing with t3151 because it's non specific and hits everything. Citing an 80% response rate is deceptive since the complete cytogenetic response rate has only been 20% and not durable. For chronic phase patients 70% had a grade 3-4 toxicity with only a 10% complete cytogenetic response and just 6 months duration. But don't believe me. Wait for the briefing documents come out.
As far as your questions, the trial started in January. And even if approved i believe it will have minimal if any bearing on enrolling clinical studies for t315i patients.
News 
Market Data 
Discover 
AI
